{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"13"}]}],"title":"6 months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"6"}]}],"title":"12 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"25"}],"units":"Participants"}],"description":"A secondary efficacy endpoint is Clinical Benefit Rate (CBR) assessed by IRR. CBR is defined as the number of patients without radiographic progression (defined by modified RECIST Version 1.1/ PCWG3 criteria) who were continuing with study drug treatment through the given time interval divided by the number of patients who had the given amount of follow-up. Clinical benefit rates are summarized at 6 and 12 months.","groups":[{"description":"Patients with a deleterious BRCA (breast cancer susceptibility gene) mutation detected in their tumor.","id":"OG000","title":"BRCA Mutation"},{"description":"Patients with a deleterious ATM (ataxia telangiectasia mutated serine/threonine kinase) mutation detected in their tumor.","id":"OG001","title":"ATM Mutation"},{"description":"Patients with a deleterious CDK12 (Cyclin-dependent kinase 12) mutation detected in their tumor.","id":"OG002","title":"CDK12 Mutation"},{"description":"Patients with a deleterious CHEK2 (Checkpoint Kinase 2) mutation detected in their tumor.","id":"OG003","title":"CHEK2 Mutation"},{"description":"Patients with other deleterious HRR (homologous recombination repair) gene mutation detected in their tumor.","id":"OG004","title":"Other Gene Mutation"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients","reportingStatus":"POSTED","timeFrame":"Assessments every 8 weeks from study day 1 for the first 24 weeks, and then every 12 weeks until disease progression, death, or initiation of subsequent treatment. Total follow-up was up to approximately 3 years.","title":"Clinical Benefit Rate (CBR) by Gene Per Central Independent Radiology Review (IRR)","type":"SECONDARY","unitOfMeasure":"Participants"}